Tempest Therapeutics regains Nasdaq minimum bid price compliance

Tempest Therapeutics, Inc.

Received Nasdaq notice on April 24, 2025 confirming compliance with Listing Rule 5550(a)(2).
Rule requires minimum bid price of $1.00 per share for continued listing.
Company had previously been notified of deficiency; now resolved.
No other regulatory or operational updates provided.

item 8.01

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-098817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.